CHRO Chromocell Therapeutics Corp. Year-over-year earnings per share growth for the last twelve months
Chromocell Therapeutics (CHRO) is advancing neuromedicine through partnerships with scientific centers to develop non-opioid drugs. These collaborations enable the blocking of pain impulses via sodium channels, eliminating dependency. Quarterly EPS fluctuations illustrate the dynamics of such developments, where the value of -18.40 serves as a baseline performance indicator. The process is supported by external compound synthesis through a network of vetted international CRO contractors.
Financial and market metric breakdowns for chromocell.com (CHRO)
- market value and analyst target forecast:
- market capitalization data:
- book capitalization data:
- company liabilities and liquidity data:
Debt to Equity Chromocell Therapeutics|CHRO - Long-Term Debt to Equity|Short-Term Debt to Equity Chromocell Therapeutics Corp.|CHRO - Company Debts|Debt to Book Value Chromocell Therapeutics Corp.|CHRO - Company Long-Term Loans and Borrowings|Company Current Liabilities Chromocell Therapeutics|Quick Ratio chromocell.com
- earnings and valuation multiples indicators:
CHRO - Final Profit|Projected Future Earnings Chromocell Therapeutics|CHRO - Market Cap to Earnings|Future Price to Earnings Chromocell Therapeutics|CHRO - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Chromocell|CHRO - Operating profit EBITDA|Earnings per share for the last twelve months Chromocell Therapeutics|CHRO - Earnings per one share for the last 12 months|Quarterly EPS earnings growth chromocell.com|CHRO - Earnings per share growth rate in current year|Expected earnings per share growth for next year Chromocell Therapeutics
- revenue and sales proceeds data:
Fundamental valuation:Chromocell Therapeutics Corporation, CHRO
This indicator measures the quarterly dynamics of net earnings per share, allowing for an assessment of the rate of capital depletion and the risk of a "value trap." By analyzing the quarterly EPS trajectory, an investor can identify the financial bottom, which is critical for Chromocell Therapeutics (CHRO), as its profitability depends directly on the successful commercialization of innovative non-opioid drugs for chronic pain therapy.
Who Chromocell Therapeutics competes with
BIIB: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Bioscience Ltd) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Axsome Therapeutics, Inc. AXSM|Year-over-year net earnings per share growth for the last 12 months ACAD (ACADIA Pharmaceuticals Inc.)|XENE: Year-over-year net earnings per share trend for the last twelve months|Viking Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Supernus Pharmaceuticals (SUPN)|CPRX: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months DNLI (Denali Therapeutics)|HRMY: Quarterly EPS earnings growth|BHVN (Biohaven Pharmaceutical) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months Amylyx|Quarterly EPS earnings growth Trevi Corp|Quarterly EPS earnings growth PRAX|AVXL (anavex.com) - Year-over-year earnings per one share growth for the last 12 months|CeriBell Inc - Year-over-year net earnings per share growth for the last 12 months|PRTA (Prothena Corporation plc) - Year-over-year net earnings per share trend for the last twelve months|ALEC - Year-over-year earnings per share growth for the last twelve months|ANNX (Annexon Biosciences Inc.) - Year-over-year earnings per share growth for the last 12 months|OMER (omeros.com) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months NGNE|Year-over-year net earnings per share growth for the last 12 months ACIU|Quarterly EPS earnings growth Voyager Pharma|Year-over-year net earnings per share growth for the last 12 months NMRA (Neumora Therapeutics, Inc.)|SCLX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Tevogen Bio TVGN|Alpha Cognition Corp (ACOG) - Earnings per share growth in annualized terms for the last twelve months|CGTX: Year-over-year net earnings per share growth for the last 12 months|Inhibikase Therapeutics, Inc. - Year-over-year earnings per share growth rate for the last twelve months|SAVA: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months ASRT|COYA (coyatherapeutics.com) - Quarterly EPS earnings growth|Vistagen (VTGN) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OVID (Ovid Rx)|Year-over-year net earnings per share change for the last twelve months Acumen Pharmaceuticals, Inc.|Quarterly EPS earnings growth CRVO (CervoMed Corporation)|Year-over-year earnings per share growth rate for the last twelve months ATHE (Alterity Therapeutics Ltd)|Clene Nanomedicine - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year pepgen.com (PEPG)|JUNS: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months RLMD|ANVS (Annovis Bio Inc) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Grace Therapeutics, Inc. (GRCE)|Quarterly EPS earnings growth AIFF|Year-over-year earnings per share growth rate for the last twelve months KLTO|Year-over-year earnings per share growth for the last twelve months neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings (RVPH) - Earnings per share growth in annualized terms for the last twelve months|MetaVia Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months NeurAxis Inc NRXS|HSDT (Helius Medical Technologies Inc.) - Year-over-year net earnings per share growth for the last 12 months|Passage Bio Inc. (PASG) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Neuphoria|Year-over-year net earnings per share growth for the last 12 months Minerva Neurosciences, Inc. (NERV)|Year-over-year earnings per share growth for the last twelve months Athira (ATHA)|Addex Therapeutics - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Alzamend Neuro, Inc. ALZN|Cyclerion (CYCN) - Earnings per share growth in annualized terms for the last twelve months|PTIX - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Pasithea Therapeutics Corp KTTA|Cortigent, Inc. (CRGT) - Year-over-year earnings per share growth for the last twelve months|Avenue Therapeutics - Year-over-year earnings per one share growth for the last 12 months|BCLI (brainstorm-cell.com) - Quarterly EPS earnings growth|CARA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Eliem Therapeutics, Inc. (ELYM)|ITCI (Intra-Cellular Therapies, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth LBPH (Longboard Pharmaceuticals Inc)|Quarterly EPS earnings growth Marinus Pharma MRNS|nkgenbiotech.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months NeuroBo Pharmaceuticals, Inc.|Sage Therapeutics (SAGE) - Year-over-year earnings per share growth for the last twelve months|SNPX - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Trevena, Inc|Vigil Neuroscience (VIGL) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth WENA|Quarterly EPS earnings growth cerevel.com (CERE)
